Pluripotent stem cell-derived NK cells engineered with key surface molecules such as high-affinity noncleavable variant of CD16a were demonstrated to improve antibody-dependent cellular cytotoxicity (ADCC) properties of NK cells and contribute to tumor regression in B-cell lymphoma xenograft studies [109, 110]. The gene discussed is FCGR3A; the disease is neoplasm.